VHL suppresses UBE3B-mediated breast tumor growth and metastasis

Cell Death Dis. 2024 Jun 24;15(6):446. doi: 10.1038/s41419-024-06844-x.

Abstract

Protein homeostasis is predominantly governed through post-translational modification (PTM). UBE3B, identified as an oncoprotein, exhibits elevated protein levels in breast cancer. However, the impact of PTM on UBE3B remains unexplored. In this study, we show that VHL is a bona fide E3 ligase for UBE3B. Mechanistically, VHL directly binds to UBE3B, facilitating its lysine 48 (K48)-linked polyubiquitination at K286 and K427 in a prolyl hydroxylase (PHD)-independent manner. Consequently, this promotes the proteasomal degradation of UBE3B. The K286/427R mutation of UBE3B dramatically abolishes the inhibitory effect of VHL on breast tumor growth and lung metastasis. Additionally, the protein levels of UBE3B and VHL exhibit a negative correlation in breast cancer tissues. These findings delineate an important layer of UBE3B regulation by VHL.

MeSH terms

  • Animals
  • Breast Neoplasms* / genetics
  • Breast Neoplasms* / metabolism
  • Breast Neoplasms* / pathology
  • Cell Line, Tumor
  • Cell Proliferation
  • Female
  • HEK293 Cells
  • Humans
  • Lung Neoplasms / genetics
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / pathology
  • Lung Neoplasms / secondary
  • Mice
  • Mice, Nude
  • Neoplasm Metastasis
  • Protein Binding
  • Ubiquitin-Protein Ligases* / genetics
  • Ubiquitin-Protein Ligases* / metabolism
  • Ubiquitination*
  • Von Hippel-Lindau Tumor Suppressor Protein* / genetics
  • Von Hippel-Lindau Tumor Suppressor Protein* / metabolism

Substances

  • Ubiquitin-Protein Ligases
  • VHL protein, human
  • Von Hippel-Lindau Tumor Suppressor Protein
  • UBE3B protein, human